Dossier assessment

Benralizumab (hypereosinophilic syndrome) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A26-87
Last updated

Report documents

  1. Extract of dossier assessment

    Benralizumab (hypereosinophilic syndrome) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 128 kB, DE, not accessible
  2. Dossier assessment

    Benralizumab (hypereosinophilic syndrome) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 481 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-87

Dossier assessment

Indication:

Adults and adolescents aged 12 years and older weighing at least 35kg with inadequately controlled hypereosinophilic syndrome (HES) without an identifiable non-haematologic secondary cause

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A26-87
Commission
Commission awarded on 15.07.2026 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Haematology
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A26-87

Connected Projects

  1. Dossier assessment

    Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-11
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Benralizumab (eosinophilic granulomatosis with polyangiitis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-113
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form